KA
Kinnariben Alpeshkumar Rana
About Kinnariben Alpeshkumar Rana
Data last updated:
Kinnariben Alpeshkumar Rana has 8 years in corporate governance. Holds Director role. Currently with 1 company, including Excalibur Healthcare Private Limited. Engaged in Healthcare. Contributes to corporate operations. The largest current company by reported revenue is Excalibur Healthcare Private Limited at ₹4.38 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Excalibur Healthcare Private Limited U85100GJ2015PTC084941 | Director | 21 Mar 2018 | 2015 | ₹4.38 Cr (FY 2024) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kinnariben Alpeshkumar Rana
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kinnariben Alpeshkumar Rana
Kinnariben Alpeshkumar Rana has 8 years in corporate governance. Holds Director role. Currently with 1 company, including Excalibur Healthcare Private Limited. Engaged in Healthcare. Contributes to corporate operations. The largest current company by reported revenue is Excalibur Healthcare Private Limited at ₹4.38 Cr (FY 2024).
Kinnariben Alpeshkumar Rana is associated with 1 company as Director, including Excalibur Healthcare Private Limited (₹4.38 Cr).
Kinnariben Alpeshkumar Rana has expertise in Healthcare.
Kinnariben Alpeshkumar Rana has 8 years in corporate governance.
By reported revenue, the largest current company of Kinnariben Alpeshkumar Rana is Excalibur Healthcare Private Limited, with revenue of ₹4.38 Cr (FY 2024).
Kinnariben Alpeshkumar Rana currently holds positions at 1 company: Excalibur Healthcare Private Limited (₹4.38 Cr).